newsfilter
← Latest News
Business Wire·

Baxalta Expands Global Reach of ADYNOVATE for Hemophilia A Patients with Approval in Japan

BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that the Ministry of Health, Labour and Welfare in Japan approved ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment, for patients 12 years and older with hemophilia A.